share_log

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $45 Price Target

Benzinga ·  Oct 4, 2024 18:30  · Ratings

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $45 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment